Abstract:Structural transitions in the prion protein from the cellular form, PrPC, into the pathological isoform, PrPSc, are regarded as the main cause of the transmissible spongiform encephalopathies, also known as prion diseases. Hence, discovering and designing effective antiprion drugs that can inhibit PrPC to PrPSc conversion is regarded as a promising way to cure prion disease. Among several strategies to inhibit PrPC to PrPSc conversion, stabilizing the native PrPC via specific binding is believed to be one of the valuable approaches and many antiprion compounds have been reported based on this strategy. However, the detailed mechanism to stabilize the native PrPC is still unknown. As such, to unravel the stabilizing mechanism of these compounds to PrPC is valuable for the further design and discovery of antiprion compounds. In this study, by molecular dynamics simulation method, we investigated the stabilizing mechanism of several antiprion compounds on PrPC that were previously reported to have specific binding to the "hot spot" region of PrPC. Our simulation results reveal that the stabilization mechanism of specific binding compounds can be summarized as (I) to stabilize both the flexible C-terminal of α2 and the hydrophobic core, such as BMD42-29 and GN8; (II) to stabilize the hydrophobic core, such as J1 and GJP49; (III) to stabilize the overall structure of PrPC by high binding affinity, as NPR-056. In addition, as indicated by the H-bond analysis and decomposition analysis of binding free energy, the residues N159 and Q160 play an important role in the specific binding of the studied compounds and all these compounds interact with PrPC in a similar way with the key interacting residues L130 in the β1 strand, P158, N159, Q160, etc. in the α1-β2 loop, and H187, T190, T191, etc. in the α2 C-terminus although the compounds have large structural difference. As a whole, our obtained results can provide some insights into the specific binding mechanism of main antiprion compounds to the "hot spot" region of PrPC at the molecular level and also provide guidance for effective antiprion drug design in the future.

Experiment and Molecular Dynamics Simulations Reveal Proanthocyanidin B2 and B3 Can Inhibit Prion Aggregation by Different Mechanisms.

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.

Interaction Between 14-3-3β and PrP Influences the Dimerization of 14-3-3 and Fibrillization of PrP106-126.

Experimental and Theoretical Insights into the Inhibition Mechanism of Prion Fibrillation by Resveratrol and Its Derivatives

Infection of Prions and Treatment of PrP106–126 Alter the Endogenous Status of Protein 14-3-3 and Trigger the Mitochondrial Apoptosis Possibly via Activating Bax Pathway

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Molecular Interaction of Tppp with Prp Antagonized the Cytoprp-Induced Disruption of Microtubule Structures and Cytotoxicity

Carbon Nanoparticles Inhibit the Aggregation of Prion Protein as Revealed by Experiments and Atomistic Simulations.

Manganese-induced Changes of the Biochemical Characteristics of the Recombinant Wild-Type and Mutant PrPs

Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods

Inhibitory Effects of Sesquiterpene Lactones on the Aggregation and Cytotoxicity of Prion Neuropeptide

The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein

Roles of Apigenin and Nepetin in the Assembly Behavior and Cytotoxicity of Prion Neuropeptide PrP106-126.

Comparison of the Unfolding and Oligomerization of Human Prion Protein under Acidic and Neutral Environments by Molecular Dynamics Simulations

Molecular Dynamics Simulation Study on the Binding and Stabilization Mechanism of Antiprion Compounds to the “hot Spot” Region of PrPC

Computational Insights Into the Inhibition Mechanism of Proanthocyanidin B2 on Tau Hexapeptide (PHF6) Oligomer

N-terminal Prion Protein Peptides (prp(120–144)) Form Parallel In-Register Β-Sheets Via Multiple Nucleation-Dependent Pathways.

PrPSc Inhibition and Cellular Protection of DBL on a Prion-Infected Cultured Cell via Multiple Pathways

Distinct Effects of Mutations on Biophysical Properties of Human Prion Protein Monomers and Oligomers.

Characterizing antiprion compounds based on their binding properties to prion proteins: Implications as medical chaperones

Inhibition of Alzheimer’s Amyloid Toxicity with a Tricyclic Pyrone Molecule in Vitro and in Vivo